US FDA Could Have Avoided Clinical Data Waste With Authority Over All COVID-19 Trials

 
• By Derrick Gingery
  
code of federal regulations
Increased FDA clinical trial oversight could have increased the amount of regulatory-grade data during the COVID-19 pandemic. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D